Protective effects of neferine on amiodarone-induced pulmonary fibrosis in mice

European Journal of Pharmacology

Volumn 714, Issue 1-3, 2013, Pages 112-119

  Niu, Chang He ^a   Wang, Yong ^a   Liu, Jing Di ^a   Wang, Jia Ling ^a   Xiao, Jun Hua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Amiodarone; Neferine; Pulmonary fibrosis; Surfactant protein D; Th1 Th2 balance

Indexed keywords

AMIODARONE; GAMMA INTERFERON; HYDROXYPROLINE; INTERLEUKIN 4; NEFERINE; PIRFENIDONE; PREDNISOLONE; SURFACTANT PROTEIN D;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOPATHOLOGY; LUNG FIBROSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TH1 CELL; TH2 CELL;

AMIODARONE; CD4+CD25+ REGULATORY T CELLS; NEFERINE; PULMONARY FIBROSIS; SURFACTANT PROTEIN-D; TH1/TH2 BALANCE;

AMIODARONE; ANIMALS; BENZYLISOQUINOLINES; BODY WEIGHT; CELL COUNT; HYDROXYPROLINE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LUNG; MALE; MICE; PULMONARY FIBROSIS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS;

EID: 84879823286     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.06.004     Document Type: Article

References (43)

1. Ashcroft, T., Simpson, J.M., Timbrell, V., 1988. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J. Clin. Pathol. 41, 467-470. (Pubitemid 18098428)
2. Azuma, A., 2012. Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther. Adv. Respir. Dis. 6, 107-114.
3. Beasley, M.B., Franks, T.J., Galvin, J.R., Gochuico, B., Travis, W.D., 2002. Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage. Arch. Pathol. Lab. Med. 126, 1064-1070. (Pubitemid 36221844)
4. Belkaid, Y., Piccirillo, C.A., Mendez, S., Shevach, E.M., Sacks, D.L., 2002. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420, 502-507. (Pubitemid 35477041)
5. Blake, T.L., Reasor, M.J., 1995. Metabolism of amiodarone following intratracheal instillation in hamsters. Toxicol. Lett. 81, 223-228. (Pubitemid 26008362)
6. Botas, C., Poulain, F., Akiyama, J., Brown, C., Allen, L., Goerke, J., Clements, J., Carlson, E., Gillespie, A.M., Epstein, C., Hawgood, S., 1998. Altered surfactant homeostasis and alveolar type II cell morphology in mice lacking surfactant protein D. Proc. Natl. Acad. Sci. U S A 95, 11869-11874. (Pubitemid 28460506)
7. Card, J.W., Racz, W.J., Brien, J.F., Margolin, S.B., Massey, T.E., 2003. Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity. Toxicol. Sci. 75, 169-180. (Pubitemid 37098749)
8. Connolly, S.J., 1999. Evidence-based analysis of amiodarone efficacy and safety. Circulation 100, 2025-2034. (Pubitemid 29529296)
9. Dharmarajan, T.S., Shah, A.B., Dharmarajan, L., 2008. Amiodarone-induced pulmonary toxicity: potentially fatal, recognize early during life!. J. Am. Geriatr. Soc. 56, 1363-1365.
10. Douglas, W.W., Ryu, J.H., Swensen, S.J., Offord, K.P., Schroeder, D.R., Caron, G.M., DeRemee, R.A., 1998. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am. J. Respir. Crit. Care Med. 158, 220-225. (Pubitemid 28337184)
11. Dusman, R.E., Stanton, M.S., Miles, W.M., Klein, L.S., Zipes, D.P., Fineberg, N.S., Heger, J.J., 1990. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 82, 51-59. (Pubitemid 20216315)
12. Fan, K., Bell, R., Eudy, S., Fullenwider, J., 1987. Amiodarone-associated pulmonary fibrosis. Evidence of an immunologically mediated mechanism. Chest 92, 625-630. (Pubitemid 18000562)
13. Greene, K.E., Wright, J.R., Steinberg, K.P., Ruzinski, J.T., Caldwell, E., Wong, W.B., Hull, W., Whitsett, J.A., Akino, T., Kuroki, Y., Nagae, H., Hudson, L.D., Martin, T.R., 1999. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am. J. Respir. Crit. Care Med. 160, 1843-1850. (Pubitemid 30004685)
14. Gu, D.F., Li, X.L., Qi, Z.P., Shi, S.S., Hu, M.Q., Liu, D.M., She, C.B., Lv, Y.J., Li, B.X., Yang, B.F., 2009. Blockade of HERG K+ channel by isoquinoline alkaloid neferine in the stable transfected HEK293 cells. Naunyn. Schmiedebergs Arch. Pharmacol. 380, 143-151.
15. Haczku, A., Cao, Y., Vass, G., Kierstein, S., Nath, P., Atochina-Vasserman, E.N., Scanlon, S.T., Li, L., Griswold, D.E., Chung, K.F., Poulain, F.R., Hawgood, S., Beers, M.F., Crouch, E.C., 2006. IL-4 and IL-13 form a negative feedback circuit with surfactant protein-D in the allergic airway response. J. Immunol. 176, 3557-3565. (Pubitemid 43364003)
16. Herring, A.C., Hernandez, Y., Huffnagle, G.B., Toews, G.B., 2004. Role and development of TH1/TH2 immune responses in the lungs. Semin. Respir. Crit. Care Med. 25, 3-10. (Pubitemid 38296154)
17. Huang, Y., Bai, Y., Zhao, L., Hu, T., Hu, B., Wang, J., Xiang, J., 2007. Pharmacokinetics and metabolism of neferine in rats after a single oral administration. Biopharm. Drug Dispos. 28, 361-372. (Pubitemid 350020227)
18. Huaux, F., Liu, T., McGarry, B., Ullenbruch, M., Phan, S.H., 2003. Dual roles of IL-4 in lung injury and fibrosis. J. Immunol. 170, 2083-2092. (Pubitemid 36197430)
19. Hudzik, B., Polonski, L., 2012. Amiodarone-induced pulmonary toxicity. CMAJ. 184, E819.
20. Jackevicius, C.A., Tom, A., Essebag, V., Eisenberg, M.J., Rahme, E., Tu, J.V., Humphries, K., Behlouli, H., Pilote, L., 2011. Population-level incidence and risk factors for pulmonary toxicity associated with amiodarone. Am. J. Cardiol. 108, 705-710.
21. Kharabsheh, S., Abendroth, C.S., Kozak, M., 2002. Fatal pulmonary toxicity occurring within two weeks of initiation of amiodarone. Am. J. Cardiol. 89, 896-898. (Pubitemid 34241479)
22. Kidd, P., 2003. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev. 8, 223-246. (Pubitemid 37099886)
23. Kosseifi, S.G., Halawa, A., Bailey, B., Micklewright, M., Roy, T.M., Byrd, R.J., 2009. Reduction of amiodarone pulmonary toxicity in patients treated with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ther. Adv. Respir. Dis. 3, 289-294.
24. Kulmatycki, K.M., Jamali, F., 2005. Drug disease interactions: role of inflammatory mediators in disease and variability in drug response. J. Pharm. Pharm. Sci. 8, 602-625.
25. Kuruma, T., Maruyama, T., Hiramatsu, S., Yasuda, Y., Yasuda, S., Odashiro, K., Harada, M., 2009. Relationship between amiodarone-induced subclinical lung toxicity and Th1/Th2 balance. Int. J. Cardiol. 134, 224-230.
26. Liu, F., Liu, J., Weng, D., Chen, Y., Song, L., He, Q., Chen, J., 2010. CD4+CD25+Foxp3+ regulatory T cells depletion may attenuate the development of silica-induced lung fibrosis in mice. PLoS One 5, e15404.
27. Martin, W.N., Rosenow, E.R., 1988a. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 1). Chest 93, 1067-1075.
28. Martin, W.N., Rosenow, E.R., 1988b. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 2). Chest 93, 1242-1248.
29. Nikaido, A., Tada, T., Nakamura, K., Murakami, M., Banba, K., Nishii, N., Fuke, S., Nagase, S., Sakuragi, S., Morita, H., Ohe, T., Kusano, K.F., 2010. Clinical features of and effects of angiotensin system antagonists on amiodarone-induced pulmonary toxicity. Int. J. Cardiol. 140, 328-335.
30. Pan, T., Nielsen, L.D., Allen, M.J., Shannon, K.M., Shannon, J.M., Selman, M., Mason, R.J., 2002. Serum SP-D is a marker of lung injury in rats. Am. J. Physiol. Lung Cell Mol. Physiol. 282, L824-L832. (Pubitemid 34665599)
31. Papiris, S.A., Triantafillidou, C., Kolilekas, L., Markoulaki, D., Manali, E.D., 2010. Amiodarone: review of pulmonary effects and toxicity. Drug Saf. 33, 539-558.
32. Punithavathi, D., Venkatesan, N., Babu, M., 2003. Protective effects of curcumin against amiodarone-induced pulmonary fibrosis in rats. Br. J. Pharmacol. 139, 1342-1350. (Pubitemid 37026418)
33. Qian, J.Q., 2002. Cardiovascular pharmacological effects of bisbenzylisoquinoline alkaloid derivatives. Acta Pharmacol. Sin. 23, 1086-1092.
34. Raghu, G., 2006. Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches. Eur. Respir. J. 28, 463-465. (Pubitemid 44794656)
35. Schwaiblmair, M., Berghaus, T., Haeckel, T., Wagner, T., von Scheidt, W., 2010. Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect? Clin. Res. Cardiol. 99, 693-700.
36. Selman, M., Pardo, A., 2002. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Respir. Res. 3, 3.
37. Takahashi, H., Shiratori, M., Kanai, A., Chiba, H., Kuroki, Y., Abe, S., 2006. Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D. Respirology. 11 (Suppl), S51-S54.
38. Umetani, K., Abe, M., Kawabata, K., Iida, T., Kohno, I., Sawanobori, T., Kugiyama, K., 2002. SP-D as a marker of amiodarone-induced pulmonary toxicity. Intern. Med. 41, 709-712.
39. Vassallo, P., Trohman, R.G., 2007. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 298, 1312-1322. (Pubitemid 47449439)
40. Wan, J., Zhao, L., Xu, C., Zhang, S., Zhang, Z., Zeng, C., Chang, M., Xiao, J., Wang, J., 2011. Effects of neferine on the pharmacokinetics of amiodarone in rats. Biomed. Chromatogr. 25, 858-866.
41. Xiao, J.H., Zhang, J.H., Chen, H.L., Feng, X.L., Wang, J.L., 2005. Inhibitory effects of isoliensinine on bleomycin-induced pulmonary fibrosis in mice. Planta Med. 71, 225-230.
42. Zhao, L., Wang, X., Chang, Q., Xu, J., Huang, Y., Guo, Q., Zhang, S., Wang, W., Chen, X., Wang, J., 2010. Neferine, a bisbenzylisoquinline alkaloid attenuates bleomycin-induced pulmonary fibrosis. Eur. J. Pharmacol. 627, 304-312.
43. Ziesche, R., Hofbauer, E., Wittmann, K., Petkov, V., Block, L.H., 1999. A preliminary study of long-term treatment with interferon gamma-1b and low-dose pre-dnisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 341, 1264-1269. (Pubitemid 29489741)